

## March 2025 Pharmacy & Therapeutics Committee Decisions

Aspirus' Pharmacy and Therapeutics Committee (P&T) is a group of physicians and pharmacists that meet throughout the year to review and make changes to the Aspirus Medicare Formulary (approved drug list). These changes are reviewed based on clinical evidence, safety, and therapeutic guidelines. All changes that are recommended by P&T for Medicare formularies are tentative until Aspirus receives final CMS approval.

Key

PA: Prior Authorization

QL: Quantity Limit

ST: Step Therapy

NEW DRUG REVIEW			
DRUG	INDICATION	FORMULARY COVERAGE	EFFECTIVE DATE
<b>Ebglyss</b> (lebrikizumab)	for the treatment of adults and pediatric patients 12 years of age and older who weigh at least 40 kg with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.	Non-Formulary	NA
<b>Nemluvio</b> (nemolizumab)	for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis in combination with topical corticosteroids and/or calcineurin inhibitors when the disease is not adequately controlled with topical prescription therapies.	Formulary w/PA	NA
<b>Iquirvo</b> (elafibranor)	Primary biliary cholangitis (PBC) in combination with ursodiol in adults who have an inadequate response to ursodiol, or as monotherapy in patients unable to tolerate ursodiol	Non-Formulary	NA
<b>Livdelzi</b> (seladelpar)	Primary biliary cholangitis (PBC) in combination with ursodiol in adults who have an inadequate response to ursodiol, or as monotherapy in patients unable to tolerate ursodiol	Non-Formulary	NA

## March 2025 Pharmacy & Therapeutics Committee Decisions

<b>Journavx</b> (suzetrigine)	treatment of moderate to severe acute pain in adults	Non-Formulary	NA
<b>Agamree</b> (vamorolone)	the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older	Non-Formulary	NA
<b>Ohtuvayre</b> (ensifentrine)	Maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients	Non-Formulary	NA
<b>Velsipity</b> (etrasimod)	the treatment of moderately to severely active UC in adults	Non-Formulary	NA
<b>OmvoH</b> (mirikizumab-mrkz)	the treatment of adults with moderately to severely active ulcerative colitis (UC)	Non-Formulary	NA
<b>Voranigo</b> (vorasidenib) <b>PROTECTED CLASS DRUG</b>	Treatment of adult and pediatric patients age ≥ 12 years with grade 2 astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase (IDH)-1 and -2 (IDH1 and IDH2) mutation following surgery including biopsy, sub-total resection, or gross total resection.	Formulary w/PA	NA

**Formulary changes for New Generics, New Indications and Miscellaneous Previously Reviewed drugs are effective 4/1/2025.**

NEW INDICATIONS REVIEW		
DRUG	CURRENT FORMULARY STATUS	RECOMMENDATION
<b>Tagrisso</b> (osimertinib) 40 mg & 80 mg tablets received a new indication for	Formulary	No change

## March 2025 Pharmacy & Therapeutics Committee Decisions

<p>adults with locally advanced, unresectable (stage III) NSCLC whose disease has not progressed during or following platinum-based chemoradiation and whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations.</p>		
<p><b>Scemblix</b> (asciminib) 20, 40, &amp; 100 mg tablets was recently granted an accelerated approval for the first-line treatment of chronic phase chronic myeloid leukemia, previously only approved for 3rd-line use or for patients harboring the T315I mutation.</p>	<p>Formulary</p>	<p>No change</p>
<p><b>Bimzelx</b> (bimekizumab) 160 mg/mL SQ injection was recently granted an approval for the treatment of adults with moderate to severe hidradenitis suppurativa (HS).</p>	<p>Non- Formulary</p>	<p>No change</p>
<p><b>Vtama</b> (tapinarof) 1% cream received approval for the treatment of atopic dermatitis in adults and pediatric patients <math>\geq</math> 2 years of age.</p>	<p>Non- Formulary</p>	<p>No change</p>
<p><b>Braftovi</b> (encorafenib) 75 mg capsule for use in combination with cetuximab and mFOLFOX6 therapy for patients with mCRC and a BRAF V600E mutation.</p>	<p>Formulary</p>	<p>No change</p>
<p><b>Imcivree</b> (setmelanotide) 10 mg/mL SC injection for syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS) or POMC, PCSK1, LEPR deficiency. Age expansion – reduced from 6 years to 2 years of age</p>	<p>Non- Formulary</p>	<p>No change</p>
<p><b>Zepbound</b> (tirzepatide) SC injections for moderate to severe obstructive</p>	<p>Non- Formulary</p>	<p>No change</p>

## March 2025 Pharmacy & Therapeutics Committee Decisions

sleep apnea (OSA) in adults with obesity		
<b>Trikafta</b> (elexacaftor-tezacaftor-ivacaftor) tablets & oral granules received a label expansion for 94 additional CFTR mutations that are responsive to treatment in patients with cystic fibrosis.	Formulary	No change
<b>Arixtra</b> (fondaparinux) SC prefilled syringes for venous thromboembolism in pediatric patients $\geq 1$ year old (age expansion)	Formulary	No change
<b>Invokana</b> (canagliflozin) & <b>Invokamet</b> [XR] (canagliflozin/metformin) for type 2 diabetes in patients $\geq 10$ years age expansion	Non- Formulary	No change
<b>Gemtesa</b> (vibegron) 75 mg tablet for overactive bladder (OAB) in adult males on pharmacologic therapy for benign prostatic hyperplasia (BPH)	Formulary	No change
<b>OmvoH</b> (mirikizumab) 100mg/mL SQ injection for moderately to severely active Crohn's disease	Non- Formulary	No change
<b>Lumakras</b> (sotorasib) and <b>Vectibix</b> (panitumumab) received a new indication to be used in combination to treat patients with KRAS G72-C mutated metastatic colorectal cancer (mCRC) who have progressed on standard chemotherapy regimens. Vectibix is a medical drug.	Formulary	No change

## March 2025 Pharmacy & Therapeutics Committee Decisions

<p><b>Calquence</b> (acalabrutinib) for MCL in adults who have received 1 prior therapy traditional approval &amp; in combination with bendamustine and rituximab for adults with previously untreated MCL who are ineligible for autologous HSCT.</p>	Formulary	No change
<p><b>Ozempic</b> (semaglutide) to reduce the risk of kidney disease worsening, kidney failure, and death from CV disease in adults with type 2 diabetes and CKD</p>	Formulary	No change
<p><b>Spravato</b> (esketamine) 28 mg nasal spray received an expanded indication to be used as monotherapy for treatment resistant depression (TRD).</p>	Formulary	No change

NEW GENERICS REVIEW		
DRUG	RATIONALE/ALTERNATIVE	RECOMMENDATION
<p><b>Betimol</b> (timolol) 0.5% ophthalmic solution for elevated intraocular pressure in glaucoma</p>	<p>A generic timolol hemihydrate 0.5% ophthalmic solution has launched</p>	Non-Formulary
<p><b>Simlandi</b> (adalimumab-ryvk) 40 mg/0.4 mL, 20mg/0.2 mL &amp; 80 mg/0.8 mL prefilled syringe for various inflammatory conditions</p>	<p>Prefilled syringes of Simlandi are now available. They are priced at parity with the currently covered pen devices. Not addressed by the PDL currently</p>	Formulary
<p><b>Adalimumab-adaz</b> 20 mg/0.2 mL prefilled syringe &amp; 80 mg/0.8 mL autoinjector for various inflammatory condition (Hyrimoz biosimilar)</p>	<p>New 20 mg/0.2 mL prefilled syringe and 80 mg/0.8 mL auto-injector dosage forms of adalimumab-adaz (generically named Hyrimoz equivalent)</p>	Non-Formulary
<p><b>Wezlana</b> (ustekinumab-auub)</p>	<p>Amgen will only be distributing</p>	Non-Formulary

## March 2025 Pharmacy & Therapeutics Committee Decisions

45 mg/0.5 mL & 90 mg/mL SC vials & prefilled syringes for various inflammatory conditions	Wezlana through a private labeler associated with Optum, and the product will only be available at their specialty pharmacy.	
<b>Victoza</b> (liraglutide) 18 mg/3 mL pen for type 2 diabetes	The first true generic of liraglutide has launched to join the authorized generic product that has been available since late June.	Non-Formulary
<b>Motegrity</b> (prucalopride) 1 & 2 mg tablets for chronic idiopathic constipation	A generic prucalopride has launched from a single manufacturer. The product has launched at a small 15% discount to brand.	Non-Formulary
<b>Nypozi</b> (filgrastim-txid) 300 mcg/0.5 mL & 480 mcg/0.8 mL prefilled syringe for neutropenia	New biosimilar for Neupogen, higher net cost than formulary products	Non-Formulary
<b>Nexium</b> (esomeprazole) 2.5 mg & 5 mg DR granules for GERD and hypersecretory conditions	The last 2 brand-only strengths of Nexium granules for oral suspension have seen generic launches.	Non-Formulary
<b>Namzaric</b> (memantine-donepezil) 14-10 mg & 28-10 mg ER capsules for Alzheimer's disease	A generic version of the extended-release formulation of Namzaric has launched at a nominal price reduction.	Non-Formulary
<b>Mesnex</b> (mesna) 400 mg tablet for ifosfamide induced hemorrhagic cystitis	A generic version of Mesnex has launched at approximately a 20% discount to the branded product.	Formulary
<b>Spritam</b> (levetiracetam) 250 mg disintegrating tablet for seizures (authorized generic)	Prasco has launched an authorized generic for Spritam, with a substantially higher WAC price.	Non-Formulary
<b>Fulvicin</b> (griseofulvin) 165 mg tablet for dermatophyte infections	The new 165mg generic strength is approximately 10-20x higher cost than similar strength tablets or the oral suspension	Non-Formulary

## March 2025 Pharmacy & Therapeutics Committee Decisions

New or Expanded Formulations		
DRUG	RATIONALE/ALTERNATIVE	RECOMMENDATION
<b>Neffy</b> (epinephrine) 2 mg/0.1 mL nasal spray for allergic reactions	Neffy is the first non-injectable (nasal spray) form of epinephrine for treatment of anaphylaxis	Formulary
<b>Augtyro</b> (repotrectinib) 160 mg capsule for ROS1+ NSCLC and NTRK solid tumors	A new 160 mg strength of repotrectinib launched joining the 40 mg capsule.	Formulary
<b>Lumakras</b> (sotorasib) 240 mg tablet for KRAS G12C-mutated NSCLC	A new 240 mg strength of sotorasib launched at the same cost per milligram as the 120 mg and 320 mg tablet.	Formulary
<b>Emrosi</b> (minocycline) 40 mg ER capsule for rosacea	Branded minocycline product specifically indicated for the treatment of rosacea in adults. Generic minocycline available.	Non- Formulary
<b>Tramadol</b> 75 mg tablet for pain	A new 75 mg tramadol tablet has launched at \$4.34 per tablet.	Non- Formulary
<b>Opipza</b> (aripiprazole) 2, 5, & 10 mg oral films for schizophrenia, MDD, Tourette's disorder, & irritability associated with autistic disorder	Opipza is a 505(b)(2) approved version of aripiprazole that is available as an oral film in 2 mg, 5 mg, and 10 mg strengths. Cover tablets and ODT versions.	Non- Formulary
<b>Danziten</b> (nilotinib tartrate) 71 mg & 95 mg tablets for Ph+ CML	Danziten is a 505(b)(2) pathway-approved tartrate salt formulation of Tasigna (nilotinib).	Non- Formulary
<b>Imkeldi</b> (imatinib) 80 mg/mL oral solution for various cancers	Liquid formulation at a much higher cost than the generic 100 mg and 400 mg imatinib tablets.	Non- Formulary
<b>Labetalol</b> 400 mg tablet for hypertension	New strength at ~4x the cost of 200mg tablets	Non- Formulary
<b>Qlosi</b> (pilocarpine) 0.4% ophthalmic solution for	A new strength of pilocarpine (0.4%) indicated for presbyopia	Non- Formulary

## March 2025 Pharmacy & Therapeutics Committee Decisions

presbyopia	(inability to focus sight on near objects) has launched.	
<b>Bimzelx</b> (bimekizumab) 320 mg/2 mL prefilled syringe & auto-injector for plaque psoriasis & hidradenitis suppurativa	A new 320 mg strength launched for bimekizumab	Formulary
<b>Erzofri</b> (paliperidone pamoate) ER suspension prefilled syringes for schizophrenia	New paliperidone palmitate ER prefilled syringes. Invega Sustenna is covered	Non- Formulary
<b>Methotrexate</b> 100 mg/40 mL IV solution for autoimmune & inflammatory disorders	New IV formulation that can be used orally	Formulary
<b>Gabarone</b> (gabapentin) 100 mg & 400 mg tablets for seizures and postherpetic neuralgia	Gabarone is a recently launched branded gabapentin product. Gabarone has a higher price vs generically available gabapentin capsules.	Non-Formulary
<b>Jivi</b> (recombinant antihemophilic	New strength	Formulary
<b>Esperoct</b> (recombinant antihemophilic factor, glycopegylated-exei) 4000 unit IV vials for hemophilia A	A new strength vial of Esperoct has recently launched.	Formulary
<b>Metformin</b> 750 mg tablet for type 2 diabetes	New strength with WAC of \$61.11/tablet	Non- Formulary
<b>Topiramate</b> 50 mg sprinkle capsule for seizures & migraine	A new branded 50 mg topiramate sprinkle capsule launched, previously generically available as 15 mg and 25 mg sprinkle capsules. WAC is 5x higher than other strengths	Non- Formulary
<b>Amantadine</b> 50 mg/5 mL & 100mg/10 mL oral solution for	An additional NDC for 50 mg/5 mL oral solution of amantadine	Formulary



## March 2025 Pharmacy & Therapeutics Committee Decisions

influenza A, Parkinson's disease, & drug-induced extrapyramidal reactions	recently launched	
<b>Fenopron</b> (fenoprofen) 300 mg capsule for pain	New branded fenoprofen	Non- Formulary
<b>Prevymis</b> (letermovir) 20 mg & 120 mg pellet packs for CMV Prophylaxis	Oral pellet packets containing 20 mg or 120 mg of letermovir per packet have launched, following the recently reported pediatric age expansion.	120mg: Formulary 20mg: Non- Formulary
<b>Metronidazole</b> 125 mg tablet to treat infections	A new 125 mg strength tablet at over 100x the cost per mg compared to alternative tablet strengths.	Non- Formulary

ADDITIONAL ITEMS REVIEWED	
ITEM	DRUGS WITH NEW POLICIES
New Medical Drug Policies (effective 4/1/2025)	<ul style="list-style-type: none"> <li>Bizengri</li> <li>Aucatzyl</li> <li>Ziihera</li> <li>Datroway</li> <li>Kebilidi</li> <li>Ryoncil</li> <li>Unloxcyt</li> <li>Opdivo Qvantig</li> </ul>